Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

NCT04507906 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
Checkpoint Inhibitor

Interventions

DRUG: Nivolumab Combined with Anlotinib

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]